Carlsmed, Inc. (NASDAQ:CARL) Short Interest Update

Key Points

• Short interest in Carlsmed, Inc. increased by 48.0% in September, reaching a total of 744,800 shares, with a short-interest ratio of 3.5 days.
• Carlsmed reported a quarterly loss of ($1.47) earnings per share, which beat the consensus estimate, while revenues reached $12.08 million.
• Weiss Ratings initiated coverage on Carlsmed with a "sell (e)" rating, contributing to a consensus rating of "Sell" for the stock.

Carlsmed, Inc. (NASDAQ:CARL - Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 744,800 shares, an increase of 48.0% from the September 15th total of 503,100 shares. Based on an average trading volume of 213,100 shares, the short-interest ratio is presently 3.5 days. Currently, 7.7% of the shares of the company are short sold. Currently, 7.7% of the shares of the company are short sold. Based on an average trading volume of 213,100 shares, the short-interest ratio is presently 3.5 days.

Carlsmed Stock Down 1.5%

Shares of CARL opened at $13.89 on Thursday. Carlsmed has a 12-month low of $11.81 and a 12-month high of $16.20.

Carlsmed (NASDAQ:CARL - Get Free Report) last released its quarterly earnings data on Thursday, August 28th. The company reported ($1.47) earnings per share for the quarter, beating the consensus estimate of ($1.52) by $0.05. The firm had revenue of $12.08 million during the quarter, compared to the consensus estimate of $11.98 million.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings initiated coverage on shares of Carlsmed in a research report on Thursday, October 16th. They set a "sell (e)" rating on the stock. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of "Sell".

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.